The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

Annals of Hematology

Volumn 94, Issue 2, 2015, Pages 177-186

  Gratwohl, Alois ^a   Baldomero, Helen ^a   Passweg, Jakob ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Allogeneic; Autologous; Chronic myeloid leukemia; Hematopoietic stem cell transplantation; Risk assessment

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADVANCED CANCER; ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DRUG TREATMENT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; BLOOD AUTOTRANSFUSION; DISEASE COURSE; DRUG RESISTANCE; ENZYMOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE;

ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION, AUTOLOGOUS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RISK ASSESSMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 84925937033     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2313-3     Document Type: Review

References (69)

1. Schiffer CA (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 357(3):258–265
2. Jabbour E, Kantarjian H (2014) Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 89(5):547–556. doi:10.1002/ajh.23691
3. Hehlmann R (1998) A chance of cure for every patient with chronic myeloid leukemia? N Engl J Med 338(14):980–982. doi:10.1056/NEJM199804023381409
4. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, Investigators IRIS (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004
5. Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP, IRIS investigators (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19):3758–3765. doi:10.1182/blood-2010-03-273979
6. Jain N, O’Brien S (2013) The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment. Expert Rev Hematol 6(5):575–586. doi:10.1586/17474086.2013.835697
7. Gugliotta G, Castagnetti F, Apolinari M, Pirondi S, Cavo M, Baccarani M, Rosti G (2014) First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs 74(6):627–643
8. Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354:1813–1826
9. Appelbaum FR (2007) Hematopoietic-cell transplantation at 50. N Engl J Med 357:1472–1475
10. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AA (1984) Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1(8378):665–668
11. Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Kröger N, Farge-Bancel D, Gaspar HB, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A (2013) European group for blood and marrow transplantation. Bone Marrow Transplant 48(9):1161–1167. doi:10.1038/bmt.2013.51
12. Mackinnon S, Goldman JM (1987) Bone marrow transplantation for CML. Baillieres Clin Haematol 1(4):1055–1076
13. Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, Dreyling M (2013) ESMO guidelines working group. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Onco 24(Suppl 6):vi133–vi137. doi:10.1093/annonc/mdt297
14. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A (2014) European myeloma network. European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99(2):232–242. doi:10.3324/haematol.2013.099358
15. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091–2101. doi:10.1056/NEJMoa1004383
16. Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P, Baldomero H, Chabannon C, Apperley J, Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation, and the European Leukemia Net (2014) Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Haematologica 99(5):908–915
17. Fefer A, Einstein AB, Thomas ED, Buckner CD, Clift RA, Glucksberg H, Neiman PE, Storb R (1974) Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med 290(25):1389–1393
18. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J et al (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314(4):202–207
19. Gratwohl A, Schwendener A, Baldomero H et al (2010) Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica 95:637–643
20. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic leukemia working party of the European group for blood and marrow transplantation. Lancet 352(9134):1087–1092
21. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, Dini G, Rocha V, Passweg J, Sureda A, Tichelli A, Niederwieser D (2009) Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 115(20):4715–4726. doi:10.1002/cncr.24531
22. Gratwohl A (2012) The EBMT risk score. Bone Marrow Transplant 47(6):749–756
23. Gratwohl A, Goldman J, Gluckman E, Zwaan F (1985) Effect of splenectomy before bone-marrow transplantation on survival in chronic granulocytic leukaemia. Lancet 2(8467):1290–1291
24. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304(25):1529–1533
25. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12):2462–2465
26. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from. HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolatemofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4):1620–1629
27. Gratwohl A, Baldomero H, Aljurf M et al (2010) Hematopoietic stem cell transplantation: a global perspective. JAMA 303(16):1617–1624
28. Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz M, Kodera Y, Lipton J, Iida M, Pasquini MC, Passweg J, Szer J, Madrigal A, Frauendorfer K, Niederwieser D, Worldwide Network of Blood and Marrow Transplantation (WBMT) (2013) Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 98(8):1282–1290. doi:10.3324/haematol.2012.076349
29. Pasquini MC (2012) Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology 17(Suppl 1):S79–S82
30. López-Hernández MA, Alvarado-Ibarra M, González-Avante CM (2011) Overall survival of chronic myeloid leukemia patients treated with related donor hematopoieticstemcell transplant or imatinib. Rev Invest Clin 63(5):494–499
31. Butturini A, Keating A, Goldman J, Gale RP (1990) Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet 335(8700):1255–1258
32. Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A (1994) Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European group for bone marrow transplantation. Chronic leukemia working party of the EBMT. Bone Marrow Transplant 14(3):407–410
33. Autograft Trials Collaboration CML (2007) Autologous stem cell transplantation in chronic myeloid leukaemia: a meta-analysis of six randomized trials. Cancer Treat Rev 33(1):39–47
34. Heim D, Gratwohl A (2008) Role of allogeneic transplantation in chronic myeloid leukemia. Expert Rev Hematol 1(1):41–50. doi:10.1586/17474086.1.1.41
35. Sorror ML (2010) Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hemato lEduc Program 2010:237–247
36. Spellman S, Setterholm M, Maiers M, Noreen H, Oudshoorn M, Fernandez-Vina M, Petersdorf E, Bray R, Hartzman RJ, Ng J, Hurley CK (2008) Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplan 14:37–44
37. Latham K, Little AM, Madrigal JA (2014) An overview of HLA typing for hematopoietic stem cell transplantation. Methods Mol Biol 1109:73–85
38. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, Shaw BE (2014) Unrelated adult stem cell donor medical suitability: recommendations from the world marrow donor association clinical working group committee. Bone Marrow Transplant. doi:10.1038/bmt.2014.67
39. Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh M (2013) CMV reactivation after allogeneic. HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122(7):1316–1324
40. Bar M, Radich J (2013) Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia. J Natl Compr Canc Netw 11(3):308–315
41. Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N (2013) Outcome of allogeneic. SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol 92(4):487–496
42. Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D (2012) Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 119(17):4083–4090
43. Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim D, Uhm J, Lambie A, Ellis L, Lipton JH (2014) A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 14:87–92
44. Lee SJ, Kukreja M, Wang T, Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT (2008) Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112(8):3500–3507
45. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Muller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10):1880–1885. doi:10.1182/blood-2009-08-237115
46. Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M (2014) Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 4, CD010189. doi:10.1002/14651858.CD010189.pub2
47. Eapen M, Logan BR, Appelbaum FR et al (2014) Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2014.09.006
48. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ (2012) Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 47(6):810–816
49. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B et al (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84(12):4064–4077
50. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Loffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109(11):4686–4692. doi:10.1182/blood-2006-11-055186
51. Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb HJ, Hasford J, Gratwohl A, Hehlmann R; for the SchweizerischeArbeitsgemeinschaftfürKlinischeForschung (SAKK) and the German CML Study Group (2014) Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia J Cancer Res Clin Oncol Apr 10
52. Jiang Q, Xu LP, Liu DH, Liu KY, Gale RP, Zhang MJ, Jiang B, Zhang XH, Wang Y, Chen SS, Zhao XY, Chen H, Jiang H, Chen YH, Han W, Qin YZ, Liu YR, Lai YY, Lv M, Huang XJ (2013) Imatinib results in better outcomes than. HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia 27(12):2410–2413. doi:10.1038/leu.2013.159
53. Liu YC, Hsiao HH, Chang CS, Liu TC, Yang WC, Hsu JF, Huang CT, Cho SF, Wu CH, Tsai YF, Lin SF (2013) Outcome of allotransplants in patients with chronic-phase chronic myeloid leukemia following imatinib failure: prognosis revisited. Anticancer Res 33(10):4663–4667
54. Hamidieh AA, Ansari S, Darbandi B, Soroush A, Arjmandi Rafsanjani K, Alimoghaddam K, Bahosh G, Behfar M, Ghavamzadeh A (2013) The treatment of children suffering from chronic myelogenous leukemia: a comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation. Pediatr Transplant 17(4):380–386
55. Tantiworawit A, Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Abou-Mourad YR, Narayanan S, Broady RC, Forrest DL (2012) Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. Leuk Lymphoma 53(7):1321–1326
56. Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ (2011) Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 117(11):3032–3040
57. Hehlmann R (2012) How I treat CML blast crisis. Blood 120(4):737–747
58. O’Hare T, Zabriskie MS, Eiring AM, Deininger MW (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12(8):513–526. doi:10.1038/nrc3317
59. Pavlů J, Apperley JF (2013) Allogeneic stem cell transplantation for chronic myeloid leukemia. Curr Hematol Malig Rep 8(1):43–51. doi:10.1007/s11899-012-0149-7
60. Benyamini N, Rowe JM (2013) Is there a role for allogeneic transplantation in chronic myeloid leukemia? Expert Rev Hematol 6(6):759–765
61. Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981–1987
62. Gratwohl A, Brand R, Niederwieser D et al (2011) Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 29:1980–1986
63. Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CML, Group S (2014) The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 123(16):2494–2496. doi:10.1182/blood-2013-11-539742
64. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim D-W, Larson RA, Lipton JH, Mahon F-X, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884. doi:10.1182/blood-2013-05-501569
65. Mo XD, Jiang Q, Xu LP, Liu DH, Liu KY, Jiang B, Jiang H, Chen H, Chen YH, Zhang XH, Han W, Wang Y, Huang XJ (2014) Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant 49(4):576–580. doi:10.1038/bmt.2013.232
66. Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R (2012) Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess 16(42):1–277. doi:10.3310/hta16420
67. Experts in Chronic Myeloid Leukemia (2013) The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121(22):4439–4442. doi:10.1182/blood-2013-03-490003
68. Yeung KY, Gooley TA, Zhang A, Raftery AE, Radich JP, Oehler VG (2012) Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data. Bioinformatics 28(6):823–830
69. Cornelissen JJ, Gratwohl A, Schlenk RF et al (2012) The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 9:579–590